A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine
Crossref DOI link: https://doi.org/10.1007/s00280-016-3035-5
Published Online: 2016-04-21
Published Print: 2016-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Jacobs, Bart A.W.
Meulenaar, Jelte
Rosing, Hilde
Pluim, Dick
Tibben, Matthijs M.
de Vries, Niels
Nuijen, Bastiaan
Huitema, Alwin D.R.
Beijnen, Jos H.
Schellens, Jan H.M.
Marchetti, Serena
Text and Data Mining valid from 2016-04-21